Drug intelligence / Profile preview

RSV preF Protein

Development stage: Phase 2
Lead developer: Janssen Pharmaceutical
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RSV preF Protein is a vaccine component developed by Janssen Vaccines & Prevention B.V. It is designed to target the pre-fusion form of the Respiratory Syncytial Virus (RSV) F protein to elicit an immune response. The drug is being investigated for safety and immunogenicity in adults aged 60 years and older as a potential vaccine against RSV. It is administered via intramuscular injection, either alone or in combination with an Ad26.RSV.preF viral vector component.

Targets

RSV preF (Respiratory syncytial virus prefusion F glycoprotein)

Beyond the preview

Go deeper on RSV preF Protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV preF Protein.

Explore the full profile